title: Indian drug maker cuts price of three cancer drugs by between 50% and 63%.
authors.forename: Meera
authors.initials: M
authors.lastname: Kay
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics*; D000069287:Capecitabine; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000191:economics; D000077143:Docetaxel; D016527:Drug Costs / Q000706:statistics & numerical data*; D004345:Drug Industry; D000069347:Erlotinib Hydrochloride; D005472:Fluorouracil / Q000031:analogs & derivatives* / Q000191:economics; D006801:Humans; D007194:India; D011799:Quinazolines / Q000191:economics*; D043823:Taxoids / Q000191:economics*
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D000069287:Capecitabine; D000069347:Erlotinib Hydrochloride; D005472:Fluorouracil